主題

DM2第二型糖尿病的藥物臨床試驗比較(Tirzepatide v.s Semaglutide)

獄之天者 | 2021-08-07 20:33:01 | 巴幣 0 | 人氣 52

In T2D, TIRZEPATIDE was superior to SEMAGLUTIDESURPASS-2 trial Change in the glycated hemoglobin level from baseline to 40 weeks
糖化血色素改善較多,體重減輕也較多


Reductions in body weight
但有更多的腸胃道相關副作用比例
Most common adverse events were gastrointestinal

Tirzepatide at all doses was noninferior and superior to semaglutide. tirzepatide組之體重減輕量多於 semaglutide組 (least-squares mean estimated treatment difference, −1.9 kg, −3.6 kg, and −5.5 kg, respectively; P<0.001統計學上顯著). Ref:DOI: 10.1056/NEJMoa2107519

最常見之副作用比例tirzepatide 組多於 semaglutide組 (nausea噁心, 17 to 22% and 18%; diarrhea腹瀉, 13 to 16% and 12%; and vomiting嘔吐, 6 to 10% and 8%, respectively).

Tirzepatide之低血糖比例(blood glucose level, <54 mg per deciliter) 佔據 0.6% (5-mg group), 0.2% (10-mg group), and 1.7% (15-mg group); semaglutide組織低血糖比例hypoglycemia  佔據0.4%.

  
嚴重的副作用:Tirzepatide組5 ~7% semaglutide3%

創作回應

更多創作